Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

P205 SWITCH FROM OMALIZUMAB TO MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: EFFECT OF WEIGHT AND BMI

K. Chapman,G. Devouassoux,M. Liu,B. Chipps,X. Munoz,M. Bergna,A. Gruber, R. Price,S. Smith,A. Bourdin

Annals of Allergy, Asthma & Immunology（2020）

Cited 0|Views36
No score
Abstract
In the OSMO study, patients with severe eosinophilic asthma (SEA) not optimally controlled with high-dose inhaled corticosteroids and other controller(s) plus omalizumab were switched to mepolizumab. In this post hoc analysis of OSMO data we evaluated mepolizumab treatment response, by weight and body mass index (BMI).
More
Translated text
Key words
asthma,omalizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined